Cell-targeted PD-1 agonists are potent NK-cell inhibitors
BackgroundThe programmed cell death protein 1 (PDCD1 or PD-1) is a key regulatory immune checkpoint and a major target for therapeutic intervention. In oncology, antibodies blocking the PD-1 pathway are used to activate immune cells to promote anti tumour immunity while in immune-mediated inflammato...
Saved in:
| Main Authors: | Harriet C. Pope, Ana L. Chiodetti, Alice Newey, Guillaume Rieunier, David X. Overton, Eduardo Mateos-Diaz, Tara M. Mahon, Giovanna Bossi, Hussein Al-Mossawi, Charlotte Viant |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1640509/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
by: Yoshiya Ohno, et al.
Published: (2025-03-01) -
CHARACTERISTICS OF SIGNALING PATHWAYS MEDIATING A CYTOTOXIC EFFECT OF DENDRITIC CELLS UPON ACTIVATED Т LYMPHOCYTES AND NK CELLS
by: T. V. Tyrinova, et al.
Published: (2014-07-01) -
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer
by: Manh-Cuong Vo, et al.
Published: (2025-03-01) -
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
by: Lingtong Zhi, et al.
Published: (2025-02-01) -
Over-activation and dysfunction of platelet-NK cell aggregates in HIV-infected individuals
by: Meiju Deng, et al.
Published: (2025-05-01)